Secukinumab in the treatment for patients with juvenile enthesitis related arthritis non-responsive to anti-TNF treatment according the Juvenile Spondyloarthritis Disease Activity Index-Reference-Cited by-同舟云学术

Secukinumab in the treatment for patients with juvenile enthesitis related arthritis non-responsive to anti-TNF treatment according the Juvenile Spondyloarthritis Disease Activity Index

Published:2022-03-22 Issue:3 Volume:40 Page:620-624
ISSN:1593-098X
Container-title:Pathogenesis of rheumatoid arthritis: one year in review 2022
language:en
Short-container-title:

Author:

Baer Jean¹,Klotsche Jens²,Foeldvari Ivan³

Affiliation:

1. Hamburg Center for Paediatric and Adolescent Rheumatology, Am Schön Klinik Eilbek, Hamburg, Germany.

2. German Rheumatism Research Center, Berlin, Germany.

3. Hamburg Center for Paediatric and Adolescent Rheumatology, Am Schön Klinik Eilbek, Hamburg, Germany. foeldvari@t-online.de

Publisher

Clinical and Experimental Rheumatology

Subject

Immunology,Immunology and Allergy,Rheumatology

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of non-systemic juvenile idiopathic arthritis;Nature Reviews Rheumatology;2024-02-06

2. Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis: lessons from treatment in adults and the way forward;Expert Review of Clinical Immunology;2024-01-10

3. Advances in the Diagnosis and Treatment of Enthesitis-Related Arthritis;Children;2023-10-02

4. Comparison of Treatment Options for Enthesitis-Related Arthritis with the Juvenile Spondyloarthritis Disease Activity Index;Medical Bulletin of Haseki;2023-09-27

5. Secukinumab in enthesitis‐related arthritis and juvenile psoriatic arthritis;International Journal of Rheumatic Diseases;2023-08-11